|
1
|
Marini KD, Payne BJ, Watkins DN and
Martelotto LG: Mechanisms of Hedgehog signalling in cancer. Growth
Factors. 29:221–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Robbins DJ, Fei DL and Riobo NA: The
Hedgehog signal transduction network. Sci Signal. 5:re62012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Varjosalo M and Taipale J: Hedgehog:
Functions and mechanisms. Genes Dev. 22:2454–2472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katoh Y and Katoh M: Hedgehog target
genes: Mechanisms of carcinogenesis induced by aberrant hedgehog
signaling activation. Curr Mol Med. 9:873–886. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gonnissen A, Isebaert S and Haustermans K:
Targeting the Hedgehog signaling pathway in cancer: Beyond
Smoothened. Oncotarget. 6:13899–13913. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McMillan R and Matsui W: Molecular
pathways: The hedgehog signaling pathway in cancer. Clin Cancer
Res. 18:4883–4888. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li H, Li J and Feng L: Hedgehog signaling
pathway as a therapeutic target for ovarian cancer. Cancer
Epidemiol. 40:152–157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Atwood SX, Chang AL and Oro AE: Hedgehog
pathway inhibition and the race against tumor evolution. J Cell
Biol. 199:193–197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stecca B, Mas C, Clement V, Zbinden M,
Correa R, Piguet V, Beermann F, Ruiz I and Altaba A: Melanomas
require HEDGEHOG-GLI signaling regulated by interactions between
GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA.
104:5895–5900. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lauth M and Toftgård R: Non-canonical
activation of GLI transcription factors: Implications for targeted
anti-cancer therapy. Cell Cycle. 6:2458–2463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jenkins D: Hedgehog signalling: Emerging
evidence for non-canonical pathways. Cell Signal. 21:1023–1034.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shevde LA and Samant RS: Nonclassical
hedgehog-GLI signaling and its clinical implications. Int J Cancer.
135:1–6. 2014. View Article : Google Scholar
|
|
13
|
Agyeman A, Jha BK, Mazumdar T and Houghton
JA: Mode and specificity of binding of the small molecule GANT61 to
GLI determines inhibition of GLI-DNA binding. Oncotarget.
5:4492–4503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alexaki VI, Javelaud D, Van Kempen LC,
Mohammad KS, Dennler S, Luciani F, Hoek KS, Juàrez P, Goydos JS,
Fournier PJ, et al: GLI2-mediated melanoma invasion and metastasis.
J Natl Cancer Inst. 102:1148–1159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Steingrímsson E, Copeland NG and Jenkins
NA: Melanocytes and the microphthalmia transcription factor
network. Annu Rev Genet. 38:365–411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hoek KS, Schlegel NC, Eichhoff OM, Widmer
DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir
K, Schepsky A, Dummer R, et al: Novel MITF targets identified using
a two-step DNA microarray strategy. Pigment Cell Melanoma Res.
21:665–676. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vachtenheim J and Borovanský J:
‘Transcription physiology’ of pigment formation in melanocytes:
Central role of MITF. Exp Dermatol. 19:617–627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Javelaud D, Alexaki VI, Pierrat MJ, Hoek
KS, Dennler S, Van Kempen L, Bertolotto C, Ballotti R, Saule S,
Delmas V, et al: GLI2 and M-MITF transcription factors control
exclusive gene expression programs and inversely regulate invasion
in human melanoma cells. Pigment Cell Melanoma Res. 24:932–943.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pierrat MJ, Marsaud V, Mauviel A and
Javelaud D: Expression of microphthalmia-associated transcription
factor (MITF), which is critical for melanoma progression, is
inhibited by both transcription factor GLI2 and transforming growth
factor-β. J Biol Chem. 287:17996–18004. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dennler S, André J, Alexaki I, Li A,
Magnaldo T, ten Dijke P, Wang XJ, Verrecchia F and Mauviel A:
Induction of sonic hedgehog mediators by transforming growth
factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression
in vitro and in vivo. Cancer Res. 67:6981–6986. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Javelaud D, Alexaki VI, Dennler S,
Mohammad KS, Guise TA and Mauviel A: TGF-β/SMAD/GLI2 signaling axis
in cancer progression and metastasis. Cancer Res. 71:5606–5610.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Santini R, Vinci MC, Pandolfi S,
Penachioni JY, Montagnani V, Olivito B, Gattai R, Pimpinelli N,
Gerlini G, Borgognoni L, et al: Hedgehog-GLI signaling drives
self-renewal and tumorigenicity of human melanoma-initiating cells.
Stem Cells. 30:1808–1818. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Davies MA and Kopetz S: Overcoming
resistance to MAPK pathway inhibitors. J Natl Cancer Inst.
105:9–10. 2013. View Article : Google Scholar
|
|
24
|
Obenauf AC, Zou Y, Ji AL, Vanharanta S,
Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, et al:
Therapy-induced tumour secretomes promote resistance and tumour
progression. Nature. 520:368–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vlčková K, Ondrušová L, Vachtenheim J,
Réda J, Dundr P, Zadinová M, Žáková P and Poučková P: Survivin, a
novel target of the Hedgehog/GLI signaling pathway in human tumor
cells. Cell Death Dis. 7:e20482016. View Article : Google Scholar
|
|
26
|
Vachtenheim J, Sestáková B and Tuhácková
Z: Inhibition of MITF transcriptional activity independent of
targeting p300/CBP coactivators. Pigment Cell Res. 20:41–51. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Packer LM, East P, Reis-Filho JS and
Marais R: Identification of direct transcriptional targets of
(V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res.
22:785–798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Herraiz C, Journé F, Ghanem G,
Jiménez-Cervantes C and García-Borrón JC: Functional status and
relationships of melanocortin 1 receptor signaling to the cAMP and
extracellular signal-regulated protein kinases 1 and 2 pathways in
human melanoma cells. Int J Biochem Cell Biol. 44:2244–2252. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hao H, Muniz-Medina VM, Mehta H, Thomas
NE, Khazak V, Der CJ and Shields JM: Context-dependent roles of
mutant B-Raf signaling in melanoma and colorectal carcinoma cell
growth. Mol Cancer Ther. 6:2220–2229. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Smalley KS, Lioni M, Dalla Palma M, Xiao
M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, et
al: Increased cyclin D1 expression can mediate BRAF inhibitor
resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther.
7:2876–2883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Singh S, Davis R, Alamanda V, Pireddu R,
Pernazza D, Sebti S, Lawrence N and Chellappan S: Rb-Raf-1
interaction disruptor RRD-251 induces apoptosis in metastatic
melanoma cells and synergizes with dacarbazine. Mol Cancer Ther.
9:3330–3341. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Domenzain-Reyna C, Hernández D,
Miquel-Serra L, Docampo MJ, Badenas C, Fabra A and Bassols A:
Structure and regulation of the versican promoter: The versican
promoter is regulated by AP-1 and TCF transcription factors in
invasive human melanoma cells. J Biol Chem. 284:12306–12317. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Desch P, Asslaber D, Kern D, Schnidar H,
Mangelberger D, Alinger B, Stoecher M, Hofbauer SW, Neureiter D,
Tinhofer I, et al: Inhibition of GLI, but not Smoothened, induces
apoptosis in chronic lymphocytic leukemia cells. Oncogene.
29:4885–4895. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pan D, Li Y, Li Z, Wang Y, Wang P and
Liang Y: Gli inhibitor GANT61 causes apoptosis in myeloid leukemia
cells and acts in synergy with rapamycin. Leuk Res. 36:742–748.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Graab U, Hahn H and Fulda S:
Identification of a novel synthetic lethality of combined
inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
Oncotarget. 6:8722–8735. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Johannessen CM, Boehm JS, Kim SY, Thomas
SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP,
Barretina J, et al: COT drives resistance to RAF inhibition through
MAP kinase pathway reactivation. Nature. 468:968–972. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Poulikakos PI, Persaud Y, Janakiraman M,
Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al:
RAF inhibitor resistance is mediated by dimerization of aberrantly
spliced BRAF(V600E). Nature. 480:387–390. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Haq R, Yokoyama S, Hawryluk EB, Jönsson
GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R,
et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene
that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA.
110:4321–4326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang DW, Li HY, Lau WY, Cao LQ, Li Y,
Jiang XF, Yang XW and Xue P: Gli2 silencing enhances TRAIL-induced
apoptosis and reduces tumor growth in human hepatoma cells in vivo.
Cancer Biol Ther. 15:1667–1676. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kumar K, Raza SS, Knab LM, Chow CR, Kwok
B, Bentrem DJ, Popovic R, Ebine K, Licht JD and Munshi HG:
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic
cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep.
5:94892015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nagao-Kitamoto H, Nagata M, Nagano S,
Kitamoto S, Ishidou Y, Yamamoto T, Nakamura S, Tsuru A, Abematsu M,
Fujimoto Y, et al: GLI2 is a novel therapeutic target for
metastasis of osteosarcoma. Int J Cancer. 136:1276–1284. 2015.
View Article : Google Scholar
|
|
43
|
Soengas MS and Lowe SW: Apoptosis and
melanoma chemoresistance. Oncogene. 22:3138–3151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Caramel J, Papadogeorgakis E, Hill L,
Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J,
Hutchinson P, Tse G, et al: A switch in the expression of embryonic
EMT-inducers drives the development of malignant melanoma. Cancer
Cell. 24:466–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vandamme N and Berx G: Melanoma cells
revive an embryonic transcriptional network to dictate phenotypic
heterogeneity. Front Oncol. 4:3522014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Denecker G, Vandamme N, Akay O, Koludrovic
D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M,
Brochez L, et al: Identification of a ZEB2-MITF-ZEB1
transcriptional network that controls melanogenesis and melanoma
progression. Cell Death Differ. 21:1250–1261. 2014. View Article : Google Scholar : PubMed/NCBI
|
